A newly-tested vaccine demonstrates encouraging results in combating both typhoid fever and invasive *Salmonella* infections, according to findings from the first human trial released October 8, 2025. The Phase 1 study, involving a limited number of participants, suggests the vaccine is safe and elicits an immune response capable of protecting against these possibly life-threatening bacterial diseases.
Typhoid and invasive *Salmonella* disproportionately impact low- and middle-income countries, causing an estimated 11 million illnesses and over 120,000 deaths annually. Current vaccines offer limited protection or require multiple doses, hindering widespread implementation. This new vaccine candidate, if proven effective in larger trials, coudl represent a important advancement in global health, offering a more accessible and durable solution to reduce the burden of these diseases, particularly for vulnerable populations. Researchers are planning larger, Phase 2 and 3 trials to confirm these initial findings and assess long-term efficacy.
The trial, details of which were released October 8, 2025, evaluated the vaccine’s safety and ability to stimulate an immune response in a cohort of healthy adult volunteers. Preliminary data indicates the vaccine was well-tolerated, with no serious adverse events reported. Further analysis is underway to determine the optimal dosage and vaccination schedule.
